WO2025214476 - CBL-B INHIBITOR
National phase entry is expected:
Publication Number
WO/2025/214476
Publication Date
16.10.2025
International Application No.
PCT/CN2025/088516
International Filing Date
11.04.2025
Title **
[English]
CBL-B INHIBITOR
[French]
INHIBITEUR DE CBL-B
[Chinese]
Cbl-b抑制剂
Applicants **
BEIJING INNOCARE PHARMA TECH CO., LTD.
Inventors
PANG, Yucheng
CHEN, Xiangyang
Priority Data
202410437878.5
11.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2808 | |
| EPO | Filing, Examination, Granting | 16473 | |
| Japan | Filing, Examination, Granting | 2016 | |
| South Korea | Filing, Examination, Granting | 1794 | |
| USA | Filing, Examination, Granting | 5640 |
Total:
28,731
Contact Us
Abstract[English]
The present invention relates to an amide compound as a Cbl-b inhibitor or a pharmaceutically acceptable salt thereof. Specifically, the present invention relates to a compound as shown in general formula (I) or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the compound or the pharmaceutically acceptable salt thereof. The compound of the present invention can be used for treating and/or preventing Cbl-b-mediated diseases, particularly cancers.[French]
La présente invention concerne un composé amide utilisé en tant qu'inhibiteur de Cbl-b ou un sel pharmaceutiquement acceptable de celui-ci. Plus particulièrement, la présente invention concerne un composé tel que représenté par la formule générale (I) ou un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne en outre un procédé de préparation du composé ou du sel pharmaceutiquement acceptable de celui-ci. Le composé selon la présente invention peut être utilisé pour traiter et/ou prévenir des maladies médiées par Cbl-b, en particulier des cancers.[Chinese]
本发明涉及作为Cbl-b抑制剂的酰胺类化合物或其可药用的盐。具体而言，本发明涉及一种通式(I)所示的化合物或其可药用的盐。本发明还涉及所述化合物或其可药用的盐的制备方法。本发明的化合物可用于治疗和/或预防Cbl-b介导的疾病，特别是癌症。